Selecta Biosciences Inc Reports DISSOLVE Phase 3 Clinical Trials in Chronic Refractory Gout Transcript
Good morning, and welcome to the Selecta conference call on the top line results from DISSOLVE I and II, the Phase III trials of SEL-212 in chronic refractory gout. (Operator Instructions) As a reminder, this conference is being recorded.
For opening remarks, I would like to introduce Blaine Davis, Chief Financial Officer of Selecta. Please go ahead, sir.
Thanks, operator. Good morning, and welcome to today's call, where we will share with you the exciting top line results from DISSOLVE I and II, the Phase III trials of SEL-212 in chronic refractory gout. The press release announced in these top line results is available in the Investors section of Selecta's website at www.selectabio.com, and today's presentation has been posted there for your review.
Joining me on today's call are Carsten Brunn, President, and Chief Executive Officer; Peter Traber, our Chief Medical Officer; and Kei Kishimoto, Chief Scientific Officer.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |